<DOC>
	<DOCNO>NCT00988715</DOCNO>
	<brief_summary>This phase I trial study pretargeted radioimmunotherapy donor peripheral blood stem cell transplant employ fludarabine phosphate total-body irradiation ( TBI ) treat patient high-risk acute myeloid leukemia , acute lymphoblastic leukemia , myelodysplastic syndrome . Giving chemotherapy drug , fludarabine phosphate , TBI donor peripheral blood stem cell transplant help stop patient 's immune system reject donor 's stem cell . Radiolabeled monoclonal antibody combine fludarabine phosphate TBI find cancer cell kill without harm normal cell . Pretargeted radioimmunotherapy ( PRIT ) allow improved target tumor cell standard directly label antibody .</brief_summary>
	<brief_title>Donor Peripheral Blood Stem Cell Transplant Pretargeted Radioimmunotherapy Treating Patients With High-Risk Advanced Acute Myeloid Leukemia , Acute Lymphoblastic Leukemia , Myelodysplastic Syndrome</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To estimate maximum tolerate dose ( MTD ) radiation deliver via PRIT use BC8-SA ( BC8 antibody-streptavidin conjugate ) combine fludarabine ( FLU ) ( fludarabine phosphate ) , 2 Gy total body irradiation ( TBI ) , cyclosporine ( CSP ) , mycophenolate mofetil ( MMF ) , allogeneic hematopoietic cell transplant ( HCT ) patient advance acute myeloid leukemia ( AML ) , acute lymphoblastic leukemia ( ALL ) , high risk myelodysplastic syndrome ( MDS ) . SECONDARY OBJECTIVES : I . To estimate rate immune reconstitution , engraftment , donor chimerism result combine preparative regimen . II . To estimate rate disease relapse , acute graft-versus-host disease ( GvHD ) , day-100 disease-free survival patient receive PRIT use BC8-SA combined FLU , 2 Gy TBI , CSP , MMF , allogeneic HCT . III . To assess biodistribution , serum half-life , urinary excretion , tissue localization , clearance BC8-SA conjugate DOTA-biotin . IV . To assess feasibility yttrium 90 ( 90Y ) -DOTA-biotin bind BC8-SA conjugate localize hematolymphoid tissue . OUTLINE : Patients undergo pretargeted radioimmunotherapy comprise test dose BC8-SA conjugate intravenously ( IV ) day -22 indium In 111 ( 111In ) -DOTA-biotin IV day -20 , follow therapy dose BC8-SA conjugate IV day -14 90Y-DOTA-biotin IV day -12 . Patients receive fludarabine phosphate IV day -4 -2 . Patients undergo TBI peripheral blood stem cell transplantation day 0 . Patients match related donor receive cyclosporine IV day -3 56 taper day 180 mycophenolate mofetil orally ( PO ) twice daily ( BID ) day 0-27 . Patients match unrelated donor receive cyclosporine IV day -3 100 taper day 180 mycophenolate mofetil PO thrice daily ( TID ) day 0-40 taper day 96 . After completion study treatment , patient follow 6 , 9 , 12 , 18 , 24 month , annually thereafter .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Anemia , Refractory</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Anemia , Refractory , Excess Blasts</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Biotin</mesh_term>
	<criteria>Patients advance AML ALL define beyond first remission , primary refractory disease , evolve myelodysplastic myeloproliferative syndrome ; patient MDS express refractory anemia excess blast ( RAEB ) , refractory cytopenia multilineage dysplasia ( RCMD ) , RCMD ring sideroblast ( RCMDRS ) , chronic myelomonocytic leukemia ( CMML ) Patients remission must CD45expressing leukemic blast ; patient remission require phenotyping may leukemia previously document CD45 negative ( remission patient , virtually antibody bind nonmalignant cell make &gt; = 95 % nucleated cell marrow ) Patients circulate blast count le 10,000/mm^3 ( control hydroxyurea similar agent allow ) Patients must estimate creatinine clearance great 50/mL per minute Bilirubin &lt; 2 time upper limit normal Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 2 time upper limit normal Karnofsky score &gt; = 70 Eastern Cooperative Oncology Group ( ECOG ) = &lt; 2 Patients must expect survival &gt; 60 day must free active infection Patients must human leukocyte antigen ( HLA ) identical sibling donor HLAmatched unrelated donor meet standard Seattle Cancer Care Alliance ( SCCA ) and/or National Marrow Donor Program ( NMDP ) donor center criterion peripheral blood stem cell ( PBSC ) donation ; relate donor match molecular method intermediate resolution level HLAA , B , C , DRB1 accord Fred Hutchinson Cancer Research Center ( FHCRC ) Standard Practice Guidelines allele level DQB1 ; unrelated donor identify use match criterion follow FHCRC standard practice guideline limit study eligible donor allele match HLAA , B , C , DRB1 , DQB1 ( Grade 1 ) , accept one allele mismatch per standard practice grade 2.1 HLAA , B , C ; PBSC permit stem cell source DONOR : Donors must meet HLA match criterion well standard SCCA and/or NMDP , donor center criterion PBSC donation Circulating human antimouse antibody ( HAMA ) human antistreptavidin antibody ( HASA ) Prior radiation maximally tolerated level critical normal organ Patients may symptomatic coronary artery disease may cardiac medication antiarrhythmic inotropic effect Patients follow organ dysfunction : Left ventricular ejection fraction &lt; 35 % Corrected diffusion capacity lung carbon monoxide ( DLCO ) &lt; 35 % and/or receive supplemental continuous oxygen Liver abnormality : fulminant liver failure , cirrhosis liver evidence portal hypertension , alcoholic hepatitis , esophageal varix , hepatic encephalopathy , uncorrectable hepatic synthetic dysfunction evidence prolongation prothrombin time , ascites related portal hypertension , bacterial fungal liver abscess , biliary obstruction , chronic viral hepatitis , symptomatic biliary disease Patients know seropositive human immunodeficiency virus ( HIV ) Perceived inability tolerate diagnostic therapeutic procedure , particularly treatment radiation isolation Active central nervous system ( CNS ) leukemia Women childbearing potential pregnant ( betahuman chorionic gonadotropin [ bHCG ] + ) breast feed Fertile men woman unwilling use contraceptive 12 month posttransplant Patients may use vitamin supplement contain biotin time 1 week prior treatment 1 week completion treatment PRIT component Inability understand give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>